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Antigen-presenting cell (APC) activation is enhanced by vaccine adjuvants. Most vaccines are based on the assumption
that adjuvant activity of Toll-like receptor (TLR) agonists depends on direct, functional activation of APCs. Here, we
sought to establish whether TLR stimulation in non-hematopoietic cells contributes to flagellin’s mucosal adjuvant
activity. Nasal administration of flagellin enhanced T-cell-mediated immunity, and systemic and secretory antibody
responses to coadministered antigens in a TLR5-dependent manner. Mucosal adjuvant activity was not affected by
either abrogation of TLR5 signaling in hematopoietic cells or the presence of flagellin-specific, circulating neutralizing
antibodies. We found that flagellin is rapidly degraded in conducting airways, does not translocate into lung parenchyma
and stimulates an early immune response, suggesting that TLR5 signaling is regionalized. The flagellin-specific early
response of lung was regulated by radioresistant cells expressing TLR5 (particularly the airway epithelial cells). Flagellin
stimulated the epithelial production of a small set of mediators that included the chemokine CCL20, which is known to
promote APC recruitment in mucosal tissues. Our data suggest that (i) the adjuvant activity of TLR agonists in mucosal
vaccination may require TLR stimulation of structural cells and (ii) harnessing the effect of adjuvants on epithelial cells
can improve mucosal vaccines.
INTRODUCTION
Vaccine formulation requires adjuvants to increase the
immune response to antigen. A fundamental question in
vaccine research is how immunity is stimulated by adjuvants.
The most commonly used adjuvants for human vaccination by
intramuscular and subcutaneous administrations are alumi-
num salts or alum. The mechanism of action of alum has been
associated both with depot effects that facilitate antigen delivery
to the immune system and to danger signaling through innate
immune receptors like the nucleotide oligomerization domain-
like receptor (NLR) family pyrin domain containing 3 (NLRP3)
inflammasome or DNA sensors.1,2 In the past decade,
novel adjuvants that specifically target Toll-like receptors
(TLRs) or NLRs have been characterized.3,4 For example,
lipopolysaccharide (LPS), flagellin, and unmethylated CpG
DNA (CpG) that are sensed by TLR4, TLR5, and TLR9,
respectively, trigger the production of various cytokines and
chemokines.5 Thus, TLR signaling that is instrumental for the
induction of innate immunity and the concomitant ignition of
adaptive immune responses, activates several types of immune
cells or non-immune cells like epithelial cells.6 Antigen-
presenting cells (APCs) like dendritic cells (DCs) are main
responders to TLR agonists.7 The actual dogma specifies
that TLR signaling promotes functional maturation of DCs
resulting in antigen presentation to naive T and B lympho-
cytes.8 Most vaccine candidates or licensed vaccines containing
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TLR-based adjuvants (like the monophosphoryl lipid A) are
assumed to depend on direct APC activation.1
Most life-threatening pathogens target the mucosal barriers,
and hosts need to rapidly circumvent their dissemination by
regionalized immunity.9 Compared with conventional vaccines
that are delivered by intramuscular or subcutaneous routes,
mucosal vaccines specifically promote regionalized responses.10
Thus, mucosal vaccines prevent infections in an early phase
through the luminal secretion of sIgA and local T-cell
responses.10 Mucosal routes of administration require live
vaccines or specific adjuvants, i.e., mucosal adjuvants, that
are able to alter/breach the epithelial barrier and promote
immunomodulation such as enterotoxins and detoxified deri-
vatives from the cholera toxin family.10 TLR agonists have shown
potency and safety as candidate mucosal adjuvants mainly when
formulated in particles.11 The mode of action of mucosal
adjuvants, including TLR agonists, is far from being understood.
Identification of TLR-dependent mechanisms by which mucosal
adjuvants increase adaptive immunity is therefore essential for
the development of novel vaccine strategies.
Some bacterial flagellins (the major component of flagella of
many mucosal pathogens) are unique agonists for TLR5 and
NLR family CARD domain-containing protein 4 (NLRC4)-
dependent signaling.12,13 Flagellins are effective adjuvants for
T-cell-mediated and antibody responses by systemic routes of
immunization in a process dependent on TLR5 and/or NLRC4
inflammasome.14–18 Interestingly, mucosal administration of
flagellin with antigen stimulates strong antigen-specific adap-
tive immune responses, especially secretory IgG and IgA, and
serum antibodies.18–20 Most studies correlated the mucosal
adjuvant capacity of flagellin to signaling in DCs from the
intestinal or respiratory tracts.12,15,21,22 For instance, DC
stimulation by flagellin activates processing, presentation,
co-stimulatory function, and secretion of interleukin (IL)-
12, IL-23, and/or IL-6, thereby promoting activation of Th1,
Th2, and Th17 cell-, antibody-mediated immunity as well as
innate lymphoid cells.15,16,22–24 On the other hand, flagellin is a
potent stimulus for epithelial cells.12,25,26 In the mucosal
context, the epithelial cells are the first sentinel cells to be
exposed to microbes and are involved in the immediate
triggering of innate immunity by sensing through TLRs and
related innate receptors.27 We and others recently observed
that, after nasal administration of flagellin, TLR5 signaling in
radioresistant lung cells is sufficient to trigger compartmenta-
lized mucosal innate immunity, i.e., synthesis of CXCL
cytokines and recruitment of neutrophils.28 However, whether
epithelial cells are involved in the ignition of flagellin-mediated
adaptive immune responses after mucosal administration
remains to be investigated.
Here we addressed whether mucosal adaptive immunity
depends on TLR5-mediated epithelial signaling. Using
Tlr5 / chimera, we showed that adaptive immunity to nasal
administration of flagellin requires TLR5-expressing structural
cells. Indeed, TLR5 expression in the hematopoietic compart-
ment was not associated to any significant induction of mucosal
response. Bronchial and alveolar epithelial cells recapitulated
the transcriptional signature of lung response to flagellin. Our
results suggest that TLR5-dependent stimulation of epithelium
is the driving force for adjuvant activity of flagellin in the
mucosa. These findings provide further perspectives in the
development of new mucosal adjuvants.
RESULTS
Mucosal TLR5 signaling stimulates local and systemic
adaptive responses
The TLR5 agonist flagellin or its non-antigenic derivative
FliCD174-400 is an efficient adjuvant for vaccination when
delivered by the respiratory route.18,32 We studied the antibody
and T-cell response stimulated via the intranasal (i.n.) route by
flagellin formulated with various antigens including ovalbumin
(OVA), diphtheria and tetanus toxoids (DT and TT, respec-
tively), keyhole limpet hemocyanin, and the HIV-derived
recombinant GP140 protein. We found that flagellin, like
cholera toxin, the gold standard mucosal adjuvant, potentiated
the systemic and local antibody response in mice to coadmi-
nistered antigens (Figure 1 and Supplementary Figure 1
online). In serum and bronchoalveolar lavages (BALs) of
animals, levels of antigen-specific total IgG and IgG1 were
increased, whereas IgG2a or IgG2c production was unchanged
(Figures 1a and c). The levels of antigen-specific IgA in BAL
were also increased (Figure 1b). To examine the T-cell
Figure 1 Nasal administration of flagellin stimulates mucosal and
systemic adaptive immunity. C57BL/6 mice (n¼ 6–8) were immunized
intranasally at days 1 and 21 with ovalbumin (OVA) in phosphate-buffered
saline (PBS)±flagellin or cholera toxin (CT). (a–c) OVA-specific antibody
response. Serum (a) and bronchoalveolar lavage (BAL) (b, c) were
collected at day 35 and levels of OVA-specific IgG1 or IgA were
determined by ELISA. (d, e) Antigen-specific T-cell response. Mediastinal
lymph node (MdLN) cells were collected at day 10 and stimulated 72 h with
OVA, and cytokine levels in supernatant were determined by ELISA.
Results are expressed as mean±s.d. and are representative of 3–6
experiments. Statistical significance (*Po0.05) was assessed by
Mann–Whitney test compared with the PBS group.
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response, cells from mediastinal lymph nodes (MdLNs) and
spleens of animals immunized with OVA-containing vaccines
were activated ex vivo (Figures 1d and e and data not shown).
In agreement with the antibody patterns, the OVA-specific
response potentiated by flagellin was characterized by the
production of the Th2-specific cytokines IL-13 and IL-5 as well
as the Th1-specific cytokine interferon-g (IFN-g). Remarkably,
the adjuvant effect was abrogated when CD4 T cells were
depleted 24 h before i.n. immunization (data not shown). This
is consistent with previous observations showing that flagellin-
mediated adjuvant effect by nasal route depends on CD4 T
lymphocytes.18,32 Interestingly, flagellin in contrast to cholera
toxin was not able to stimulate production of IL-17A and IL-22
by spleen or lymph node cells. These findings support the idea
that flagellin activity on the mucosa enhances a mixed Th1–Th2
T-cell response as well as IgA and IgG production in serum and
secretions, a feature of mucosal adjuvants.
The activity of flagellin by i.n. route was found to depend on
TLR5 as the adjuvant effect on B- and T-cell responses was
abrogated in Tlr5 / animals (Figure 2). In contrast to
conventional animals, TLR5-deficient mice did not increase the
systemic antibody response and the local antibody response
(both IgG1 and IgA) specific for the antigen after nasal
immunization with the flagellin-formulated vaccine (Figures
2a–c). Similar observations were done with respects to the
T-cell response as defined by the secretion of IFN-g and IL-13
by MdLN cells (Figures 2d and e). However, cholera toxin
enhanced adaptive immune responses independently of TLR5
as both conventional and TLR5-deficient animals responded to
nasal vaccination. We also assessed the contribution of NLRC4
in adjuvant activity of flagellin using recombinant flagellins
harboring mutations in the C-terminal part as described
previously.33 Administration of FliC492stop deficient in NLRC4
activation was as potent as the NLRC4 competent FliCV489A
(harboring the same tag as FliC492stop) or native flagellin in
enhancing the adaptive response to OVA (Supplementary
Figures 1D and E). Altogether, our results demonstrated that
flagellin promotes TLR5-dependent adjuvant effects upon i.n.
immunization independently of the NLRC4 signaling motif.
Flagellin-mediated mucosal adaptive immunity requires
radioresistant cells
We hypothesized that the immune-adaptive responses induced
by flagellin in the respiratory tract are mediated by the
structural cells (mainly epithelial cells) as described for innate
responses.28 To challenge this model, we generated radiation
chimera by transplantation of bone marrow (BM). Irradiated
wild type (WT, C57BL/6J) and TLR5-deficient mice
were reconstituted with BM cells to obtain Tlr5 /-WT
and WT-Tlr5 / chimera and the control counterparts
Figure 2 Adjuvant effect of flagellin is TLR5 dependent. C57BL/6 and Tlr5 / mice (n¼ 4–14) were immunized intranasally at days 1 and 21 with
ovalbumin (OVA) in phosphate-buffered saline (PBS)±flagellin or cholera toxin (CT). Serum, bronchoalveolar lavage (BAL), and mediastinal lymph node
(MdLN) were collected at day 35. (a, b) OVA-specific antibody response. Levels of OVA-specific IgG1 or IgA were determined by ELISA in serum (a) and
bronchoalveolar lavages (b, c). (d, e) OVA-specific T-cell response. Lymph node cells were stimulated 72 h with OVA and cytokine levels in supernatant
were determined by ELISA. Results are expressed as mean±s.e.m. and are representative of 2 experiments. Statistical significance (*Po0.05) was
assessed by Mann–Whitney test compared to the PBS group for each mouse strain.
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Tlr5 /-Tlr5 / and WT-WT. We determined that in
Tlr5 /-WT chimera or Tlr5 / mice, splenic DCs were
responsive to LPS but not flagellin as defined by expression of
CD86 and secretion of IL-12p40 in serum (Supplementary
Figure 2). These results indicated that the hematopoietic
compartment of Tlr5 /-WT mice including the DC
compartment is deficient for flagellin/TLR5 signaling.
Although the hematopoietic cells of Tlr5 /-WT were
unable to respond to flagellin, the adjuvant activity of flagellin
using nasal route of vaccination was not altered (Figure 3). For
instance, circulating and secretory antibodies specific for the
OVA antigen were significantly enhanced by flagellin i.n.
vaccination in Tlr5 /-WT animals compared with the
group immunized with standalone antigen formulation
(Figures 3a–d). Analysis of cytokine production by OVA-
stimulated MdLN and spleen revealed that Tlr5 /-WT
animals were also potently activated by the nasal vaccines
containing flagellin (Figures 3f–h). As Tlr5 / -WT were
effectively reconstituted by donor cells (496% blood cells,
490% lung hematopoietic cells, and 495% alveolar
macrophages), we concluded that the adaptive immune
response triggered by the mucosal adjuvant flagellin is
mainly regulated by TLR5 signaling in the radioresistant
compartment. Conversely, the WT-Tlr5 / mice elicited
lower T-cell-mediated and antibody responses compared with
vaccination with flagellin and OVA. We found that antibody
response and cytokine responses were mostly abrogated or
similar to the response of Tlr5 /-Tlr5 / mice. Our data
showed also that the antibody response specific for flagellin was
strongly impaired in the various chimera compared with the
positive control WT-WT (Figure 3e). As one might expect,
the antibody response in Tlr5 /-WT chimera was
dominated by the IgG1 isotype as described for
conventional animals and Th2-type cytokines, and was
associated to production of secretory antibodies like IgA.
Altogether, our results showed that radioresistant cells are
crucial to establish the adaptive immune response to flagellin in
lung mucosa.
We previously demonstrated that either flagellin-specific
‘‘hyperimmunization’’ of animals or passive transfer of anti-
flagellin serum from ‘‘hyperimmune’’ animals is able to
neutralize the systemic activity of flagellin on innate signaling.18
Figure 3 Flagellin-mediated adjuvant activity requires TLR5-responsive radioresistant cells.C57BL/6 (WT)PWT, Tlr5 /PTlr5 / , Tlr5 /PWT
and WTPTlr5 / bone marrow chimera mice (n¼ 7–14) were immunized intranasally at days 1 and 21 with ovalbumin (OVA) or flagellinþOVA in
phosphate-buffered saline. Serum, bronchoalveolar lavage (BAL), spleen, and mediastinal lymph node (MdLN) were collected at day 35. (a–d) OVA-
specific antibody response. Levels of OVA-specific IgG, IgG1 and IgA were determined by ELISA in serum (a, b) and BAL (c, d). (e) Flagellin-specific
antibody response in serum. (f–h) OVA-specific T-cell response. MdLN or spleen cells were stimulated 72 h with OVA and cytokine levels in supernatant
were determined by ELISA. Statistical significance (*Po0.05) was assessed by Mann–Whitney test with regard to OVA-vaccinated animals for each
group (a–d and f–h) or WTPWT group (e). Results are expressed as mean±s.e.m. and are representative of 1–3 experiments. ND, not done.
ARTICLES
492 VOLUME 7 NUMBER 3 |MAY 2014 |www.nature.com/mi
Using this approach, we addressed whether flagellin needs to
access the systemic compartment to promote adjuvant activity
by i.n. route (Supplementary Figure 3). We first found that
flagellin-specific circulating antibodies impaired the activation
of splenic DCs after intravenous (IV) administration of flagellin
in contrast to control antibodies (Supplementary Figure 3A).
Similarly, the antibodies against flagellin totally blocked the
potency to induce the systemic proinflammatory response as
assessed with the CCL20 response (Supplementary Figure 3B).
Using the same conditions of neutralization, the capacity of
flagellin to increase the OVA-specific antibody response was
shown to be impaired after IV vaccination with flagellin±OVA
(Supplementary Figure 3C). However, the neutralizing
antibodies did not affect the systemic response to the TLR3
agonist poly I:C, demonstrating specificity of these findings.
Using i.n. vaccination route, we found that flagellin-specific
circulating neutralizing antibodies were not able to alter the
mucosal adjuvant activity of flagellin (Supplementary
Figure 3D). These data suggest that the mucosal adjuvant
functions of flagellin do not require the flagellin-mediated
innate signaling in the resident hematopoietic cells of lung
parenchyma, blood, or peripheral tissues. Altogether, our
experiments support the idea that structural cells of airways are
the key targets of TLR5 signaling driving the mucosal adjuvant
activity.
Flagellin is compartmentalized to the conducting airways
and is rapidly degraded
To further define the mechanisms of action of adjuvants, the
distribution of flagellin was investigated in the respiratory tract.
We took advantage of the fact that systemic delivery of flagellin
triggers an immediate IL-22 production in a process fully
dependent on TLR5 signaling in DCs.23,24 As expected, flagellin
activated within 2 h a swift and transient production of IL-22 in
the respiratory tract, in blood and in spleen when delivered by the
IV route (Figures 4a and b). In contrast, i.n. administration of a
potent dose of flagellin adjuvant was not associated with a
significant modulation of IL-22 secretion or transcription, both in
airway parenchyma, blood, and spleen. These results were not due
to delay of flagellin delivery from airways into the parenchyma or
systemic compartment as the unresponsiveness was similar at 6 h
post instillation. Although i.n. delivery of flagellin did not trigger
Il22 expression in lungs, it stimulated a strong proinflammatory
response in lung tissue (Figure 5). These results suggested that
flagellin is not translocated into the parenchymal compartment of
lungs, blood, or peripheral tissues.
We next addressed how flagellin was processed in the
airways. Lavages of the conducting airways (BAL) and lung
tissue extracts were analyzed at various times post adminis-
tration for degradation and biological activity using flagellin-
specific immunoblot and ELISA (Figures 4c–g). We first found
that flagellin was recovered in the BAL immediately after i.n.
administration (about 10–20% of the initial input). In contrast,
only 1% flagellin was recovered from the lung tissue and this
amount decreased during time, indicating that flagellin was
mainly associated with the conducting airways (Figure 4d).
Figure 4 Flagellin is rapidly and totally degraded in airways conducts.
C57BL/6 mice (n¼ 3–6) were treated intravenously or intranasally (i.n.) with
flagellin. Spleen (a) and lung (b) were sampled at 2 h and Il22 mRNA levels
were determined by quantitative PCR. Levels of mRNA in mock animal were
arbitrarily set to 1 and used to calculate relative gene expression. (c–g) Mice
(n¼3–4) were stimulated i.n. with 1mg (d, e, g) or 10mg (c, f) flagellin and
lungs and bronchoalveolar lavage (BAL) of mock or flagellin-treated mice
were sampled at indicated time. " " and "þ " indicate BAL from mock
animals and BAL supplemented ex vivo with flagellin, respectively. In panels
c–e experiments were conducted on NMRI mice, whereas Tlr5 / and
C57BL/6 (WT) animals were used for panels (f, g). (c) Kinetic of flagellin
degradation. Flagellin (upper panel) or endogenous IgG (lower panel) were
analyzed by SDS–polyacrylamide gel electrophoresis and immunoblot. For
each time, the immunoblot for two animals were shown. (d) Concentration of
flagellin was estimated by ELISA. (e) Time course analysis of flagellin activity
in sampled BAL. Epithelial cells Caco-2 were stimulated 24h with BAL
isolated from flagellin-treated mice sampling at indicated time or medium as
control ( ). Levels of IL-8 in supernatants were determined by ELISA.
Results areexpressed asmean±s.d. Statistical significance (*Po0.05) was
assessed by Mann–Whitney test compared with phosphate-buffered saline
(a, b) or t0 (e) group. (f) Flagellin degradation in BAL 2 h after nasal
administration was analyzed by flagellin-specific immunoblot. For each
group, the immunoblot for 3 animals were shown. (g) Concentration of
flagellin was estimated by ELISA at 2 and 6 h. ND, not done.
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The low amounts of lung-associated flagellin represented
either transepithelial-translocated flagellin or flagellin
attached to the epithelium. Flagellin was degraded within
hours in BAL, whereas the total BAL IgG used as a surrogate
indicator of quality of samples were stable (Figures 4c and d).
First signs of proteolysis were observed as soon as 1 h
post administration and at 12 h most protein was fully
degraded. In addition, the degradation in BAL was found
to correlate with the concomitant decrease of capacity of
flagellin to induce innate signaling, as defined on the Caco-2
cells that are potent responders to TLR5-dependent
signaling (Figure 4e). These data are consistent with the
susceptibility of native flagellin to protease activity.34,35 Finally,
we determined that the susceptibility of flagellin to degradation
was similar in Tlr5 / animals and the TLR5-sufficient
controls (Figures 4f–g), suggesting that absence of TLR5
does not impact on flagellin degradation in airways. In
conclusion, our experiments showed that after nasal admini-
stration, flagellin is mainly restrained to the conducting airways
and is rapidly degraded to inactive peptides by airways
proteases.
Flagellin activates a gene expression program specific for
regulated mucosal immune responses
TLR signaling is characterized by a swift and strong
transcriptional activation. To further define the compartments
where activation takes place, microarray experiments were
performed on whole lungs 1 h after flagellin administration, a
short period that minimized bias consequent to tissue
remodeling and immune cell infiltration (Figure 5 and
Supplementary Figure 4).28 Although, our flagellin prepara-
tions were LPS-depleted (o20 pg LPS per mg flagellin), these
experiments were conducted on the TLR4 hyporesponsive
C3H/HeJ animals to rule any effect of low levels of LPS
contamination traces on gene expression. The analysis
identified 34 genes that were differentially upregulated by
flagellin and were part of signaling pathways including TLR,
inflammation mediated by chemokine and cytokine, TGF-b,
and apoptosis. We classified the flagellin-activated genes into
three groups according to their biological function. The first
group of genes encodes cytokines like IL-1a and tumor necrosis
factor-a, chemokines like CCL3, CCL20, CXCL-1, 2, 10 as well
as CD83 and granulocyte macrophage colony-stimulating
factor associated with DC activation/differentiation. Interest-
ingly, the chemokine CCL20 is known to participate in the
recruitment of DC precursors.36 The second group includes
genes encoding transcriptional activators of innate signaling
such as JUN, FOS, and I-kBz and negative regulators of TLR
activation like TNFAIP3 (A20), I-kBa, and tristetraprolin
(ZFP36). This feature suggests that the lung response to TLR5
agonist is a highly regulated process. The third group of genes
encodes factors involved in differentiation, repair, and
resistance of cells and tissues to stress and apoptosis. This
set of genes may limit lung damage caused by cellular
infiltration and promote a rapid feedback to homeostasis.
Microarray data were validated by quantitative PCR gene
expression analysis and the correlation was highly significant
(Supplementary Figures 4A–C). This signature was not
Figure 5 TLR5 activation promotes an early and transient lung proinflammatory signature. (a) Transcriptomic analysis of lung response to flagellin.
C3H/HeJ mice (n¼ 9/group) were treated intranasally (i.n.) with phosphate-buffered saline (PBS) or flagellin. Total lung RNA was extracted 1 h later and
processed for hybridization on microarrays. Genes differentially expressed (fold increase41.5 and Po0.05) after 1 h of flagellin treatment were arbitrary
classified in three groups depending on their biological function. (b–d) Time–course analysis of pulmonary response to flagellin. C57BL/6 mice (n¼ 4–6)
were treated i.n. with PBS or flagellin. At indicated times, lung (b, c) or bronchoalveolar lavages (BAL) (d) were sampled. Levels of Ccl20 and Cxcl2 mRNA
were analyzed by quantitative PCR (b) and levels of chemokines CCL20 and CXCL2 (c, d) were determined by ELISA. Levels of mRNA in PBS-treated
animals were arbitrarily set to 1 and used to calculate relative gene expression. Results are expressed as mean±s.d. for mRNA and mean±s.e.m. for
proteins and are representative of 2–3 experiments.
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specific of C3H/HeJ mice as similar patterns of activation were
defined in C57BL/6, BALB/c, and the outbred NMRI mice
(Supplementary Figure 4E).
Next, the kinetics of the lung response to flagellin was
investigated. We determined the gene expression and protein
levels in lung (Figures 5a-b) and BAL (Figure 5c) of
chemokines CXCL2 and CCL20. A swift and transient
transcription and secretion was observed with a peak at 2
and 6 h, respectively. Interestingly, the steady-state expression
was mostly reinstated at 24 h. Such patterns of expression were
found for most genes of the signature (Supplementary
Figure 4D). Remarkably, this transient response was
observed in prime (day 1) and prime-boost experiments
(day 1 and day 21), indicating that similar innate mechanisms
are triggered by flagellin during nasal vaccination indepen-
dently of any memory adaptive response (Supplementary
Figure 4F). Therefore, the lung-specific TLR5 signature
showed that flagellin stimulates a highly regulated response
signal.
Finally, the contribution of radioresistant and hematopoietic
compartments to TLR5 signature was addressed using BM
chimera. To this aim animals were left untreated (mock) or
treated i.n. with flagellin and the level of transcriptional
activation was assessed by quantitative reverse-transcriptase–
PCR. We observed that flagellin-dependent transcription of
several genes of the TLR5-specific lung signature was fully
impaired in Tlr5 /-Tlr5 / mice compared with that in
WT-WT chimera (Figure 6). Moreover, the transcriptional
activation stimulated by flagellin was consistently higher in
Tlr5 /-WT than in Tlr5 / -WT. In conclusion, our
results show that radioresistant cells are key players for
stimulation of TLR5-dependent transcription. These data also
highlighted a strong correlation between the localization of
flagellin within the conducting airways, the early mucosal
transcriptional response stimulated by flagellin and the
mucosal adjuvant potency of flagellin-containing vaccines.
Respiratory epithelial cells are the main responder cells to
TLR5 stimulation
The lung bronchoalveolar compartment is mainly constituted
by radioresistant structural cells (epithelial cells) and resident
macrophages. Our experiments showed that the pulmonary
and alveolar macrophages are poorly responsive to flagellin in
contrast to CpG (TLR9) or LPS (TLR4) (Supplementary
Figure 5 and data not shown). For instance, macrophages
isolated from alveoli did not produce any IL-12p40 after
flagellin stimulation, whereas a significant but low level of
IL12p40 production was stimulated in pulmonary
macrophages. This is also consistent with data obtained
with peritoneal and BM-derived macrophages that are
poorly activated by flagellin in contrast to LPS or CpG,
although a significant but moderate activation of nuclear factor
(NF)-kB signaling (Supplementary Figure 5). As flagellin
induced a fast signaling, was not translocated to parenchyma,
did not activate in a significant manner the alveolar
hematopoietic cells, and was functional on the radioresi-
stant compartment, we investigate the contribution of
structural cells to the signaling. To examine this hypothesis,
microdissection of lung from phosphate-buffered saline (PBS)-
or flagellin-treated mice was performed to enrich bronchial
epithelium or whole alveolar compartment and to achieve
quantitative gene expression analysis with regard to the TLR5
signature (Figures 7a and b). Interestingly, the magnitude and
the pattern of the bronchial epithelium transcriptional response
to flagellin were similar to the response of the entire lung.
A similar transcriptional pattern was found for the whole
alveolar compartment but to a lower extent. In addition, we
found that alveolar and tracheal cells isolated from mice are
stimulated 450 fold with regard to Ccl20 expression in
response to flagellin (data not shown). This is in agreement with
recent observations indicating that mouse respiratory epithelial
cells are the main cells expressing Tlr5 mRNA and responding
to flagellin upon nasal administration.19 Furthermore, the gut
response was investigated upon luminal administration of
flagellin into ligated ileal loops (Supplementary Figure 6). In
these experiments, Ccl20 expression was also exclusively
restricted to the intestinal epithelium. To get further
insights, we studied the response of human epithelial cell
lines to flagellin stimulation. Expression of TLR5 signature-
specific genes including CCL20, CXCL1, CXCL2, IL8, NFKBIA,
NFKBIZ, TNF and TNFAIP3 was strongly upregulated in the
respiratory epithelial cells including BEAS-2B or 16HBE
(bronchial) and A549 (alveolar) (Figures 7c and d). We
found that after 24-h stimulation by flagellin, BEAS2B and
16HBE secreted significant amounts of CCL20 (flagellin:
563±63 and 642±53 pg ml 1 versus controls: 6 pg ml 1)
and IL-8 (flagellin: 1291±219 and 4,185±339 pg ml 1 versus
controls: 6 and 380±52 pg ml 1) and whereas tumor necrosis
factor was not found in BEAS-2B and barely detectable in
16HBE. These results indicated that respiratory epithelial cells
recapitulate the whole lung response. In conclusion, this study
suggests that the epithelial compartment drives the activity of
the mucosal adjuvant flagellin.
DISCUSSION
This study demonstrates that TLR5 signaling in airway
structural cells drives the flagellin-specific mucosal adjuvant
activity on adaptive immunity. We showed that the i.n.
administration of flagellin activates antibody- and T-cell-
mediated immune responses in the systemic and respiratory
compartments. The adjuvant activity was dependent on TLR5
but not on NLRC4 and correlated with TLR5 signaling in
radioresistant cells. Furthermore, flagellin was rapidly degraded
in the respiratory tract, indicating that TLR5 signaling occurs
swiftly in the airway epithelial compartment. Bronchial and
alveolar epithelial cells mostly recapitulated the flagellin-
mediated transcriptional activation of mouse lung tissue. In
conclusion, these data suggest that the airway epithelial cells
regulate the adjuvant activity of flagellin.
Various studies highlighted the contribution of epithelium to
immunity in response to microbes or microbial motifs.6,27
Pioneer in vitro works showed that intestinal epithelial cells in
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response to bacteria produce proinflammatory mediators like
the CXCL8 chemokine, and allow the recruitment of neu-
trophils into the gut lumen.37,38 Similar observations were
carried out with bronchial and alveolar epithelial cells.39 In vivo,
contribution of gut and airway epithelial cells was supported
by experiments performed with chimera or tissue-specific
Figure 6 Lung-specific TLR5 signature depends on signaling in radioresistant cells. C57BL/6 (WT)PWT, Tlr5 /-Tlr5 / , Tlr5 /-WT and
WT-Tlr5 / bone marrow chimera mice (n¼ 3–4) were treated intranasally with flagellin or untreated. Lungs were sampled at 2 h and mRNA levels
of various proinflammatory genes were analyzed by quantitative PCR. Levels of mRNA in mock animals were arbitrarily set to 1 and used to calculate
relative gene expression of flagellin-treated animals. Results are expressed as mean±s.e.m. Statistical significance (*Po0.05) was assessed by
Mann–Whitney test between Tlr5 /-WT and WT-Tlr5 / groups.
ARTICLES
496 VOLUME 7 NUMBER 3 |MAY 2014 |www.nature.com/mi
deficient mice.28,40–42 Similarly, TLR5-mediated mucosal
innate immunity was found to depend on signaling within
the epithelium compartment of mucosa.28,43 Stromal and
hematopoietic cells can crosstalk to provide effective adaptive
responses upon TLR stimulation.44,45 The epithelial or stromal
TLR signaling was associated with adaptive immunity due to
the production of mediators modulating immune cells like DCs
or lymphocytes.6,27 TLR-stimulated epithelium can regulate
DC activation via thymic stromal lymphopoietin,46 or can
condition antibody responses by production of B-cell-specific
cytokines like BAFF and APRIL.47 In response to bacterial or
TLR agonist, epithelial CCL20 stimulation attracts immature
DC precursors or lymphocytes.25,48 Le Borgne et al.36 showed
that CCR6-dependent APC recruitment is required to trigger
adaptive immunity using microbial compounds as adjuvant for
cutaneous or buccal route. The present study demonstrated that
airway epithelial cells produce CCL20 upon nasal adminis-
tration of flagellin. In the same way, the production of
granulocyte macrophage colony-stimulating factor is a major
activator of lung DC activity on antigen-specific immune
responses.49 Recent studies highlighted the contribution of
epithelial thymic stromal lymphopoietin, IL-25, and IL-33 in
the regulation of allergy in response to stimulation with antigen
and TLR4 or TLR5 agonists.19,41 Recruitment and/or activation
of lung APC by epithelial mediators may therefore represent the
mechanism promoting mucosal adjuvant activity of flagellin.
Next, investigations have to define the nature of APCs, i.e.,
monocyte or DC, that are involved in the sampling of antigen
through epithelial barrier and in the antigen presentation in
draining lymph nodes.
It is assumed that adjuvant activity of TLR agonists like the
monophosphoryl lipid A used in some commercial vaccines
depends on direct TLR-mediated signaling in APC. Reis e Sousa
et al. demonstrated that the systemic administration of TLR
agonists activates the adaptive immune response in a process
that strictly depends on TLR-mediated activation of APC in
lymphoid organs.8,50 Flagellin, like other TLR agonists,
activates APC in a TLR5-dependent manner when adminis-
tered by systemic route.15,24,40 Here we demonstrated that
adjuvant activity of flagellin when delivered by nasal route is not
affected even though TLR5 signaling is deficient in hemato-
poietic cells or flagellin activity is neutralized in the systemic
compartment. This work therefore supports the hypothesis that
adaptive immune responses induced by TLR agonists can result
Figure 7 Airway epithelial cells replicate the lung signature to flagellin
(a, b) Transcripts analysis of microdissected lung compartments.
C57BL/6 mice (n¼ 2–3) were treated i.n. with phosphate-buffered saline
or flagellin 2 h. Bronchoalveolar lavage (BAL) and lungs were sampled.
Lungs were prepared for laser microdissection of bronchial epithelium
and alveolar compartment. Level of Ccl20 mRNA (a) and others
proinflammatory genes transcripts (b) in bronchial epithelium and whole
alveolar compartments, BAL cells or total lung were determined by
quantitative PCR (qPCR). (c, d) Activation of human epithelial cells by
flagellin treatment. Normal bronchial epithelial cell line BEAS-2B were
stimulated 1 h with flagellin (c). Bronchial and alveolar epithelial cell line,
16HBE and A549, respectively, were stimulated 2 h with flagellin (d). Total
RNA was extracted and proinflammatory gene expression analyzed by
qPCR. Levels of mRNA in mock animals or cells were arbitrarily set to
1 and used to calculate relative gene expression of flagellin-treated
animals or cells. Results are expressed as mean±s.d. Statistical
significance (*Po0.05) was assessed by Mann–Whitney test.
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from indirect APC activation by TLR-induced signals in
structural cells. This feature may be specific for non-lymphoid
tissues like lungs that harbor (and recruit) APC specifically
conditioned by the environment, thereby distinguishing these
APCs from lymphoid organ APCs. Moreover, non-lymphoid
tissues are prone to strong proinflammatory signaling due to
structural cells that impact on APCs and adaptive immune
responses. Indeed, CCL20 and granulocyte macrophage
colony-stimulating factor represent potent conditioning
epithelial factors of APCs as they promote APC recruitment
or differentiation in non-lymphoid tissues.36,49 Recently,
Hammad et al.41 proposed that epithelial cells are sufficient
to drive T-cell responses in a TLR4-dependent stimulation of
the respiratory tract. Understanding how TLR4 and TLR5
condition the epithelium to manipulate signals needed for
recruitment and activation of APCs will be a major topic of
future research.
This study indicates that the TLR5-stimulating motif of
flagellin but not the NLRC4 motif is required for mucosal
adjuvant activity. In contrast, Vijay-Kumar et al.17 showed that
both TLR5 and NLRC4 could contribute to the adaptive
immune responses induced by flagellin by the systemic route.
These results suggest that the immunization route conditions
the mode of action of adjuvants.
Most adjuvants enhance immunogenicity of antigens by
eliciting a proinflammatory environment that recruits pha-
gocytic cells. Major issues are therefore the induction of
sustained inflammation.1 The i.n. administration of flagellin
induces a transient proinflammatory response into the lung.
NF-kB is an important regulator of TLR-mediated responses
that has to be controlled in a timely manner as excessive or
sustained signaling can cause tissue damage. Our analysis
showed a rapid upregulation of the expression of genes encod-
ing the TLR- and NF-kB-negative regulators A20, ZFP36, IkBa,
and ATF3.51 These regulators act along the TLR signaling
pathway, thereby blocking untimely or prolonged proinflam-
matory responses. The deubiquitinase A20 inactivates the TLR
signaling cascade.52,53 Recent data indicated that epithelial
expression of A20 is crucial to contain mucosal inflammation,
especially in the gut by protecting enterocytes from apoptosis
and resolving inflammation.54 Similarly, de novo synthesis of
I-kBa prevents nuclear localization of NF-kB.51 The tran-
scriptional repressor ATF3 inhibits the TLR-dependent
transcription of proinflammatory genes like Il6, Cxcl1, and
Cxcl2, particularly in the respiratory tract.55 The posttran-
scriptional regulator tristetraprolin encoded by Zfp36 is known
to destabilize the mRNA of Tnf or Csf2.51,56 Interestingly, after
primary flagellin administration, the lung tissue was not able to
respond for 24 h to a secondary stimulation (data not shown).
The negative regulators identified in this study could thus
participate in the process of tolerance. Finally, the rapid
degradation of flagellin is also an important feature that
promotes attenuation of TLR signaling.
Besides regulation of TLR-mediated inflammatory signaling,
the capacity of an adjuvant to induce rapid restoration of
steady-state homeostasis is an important feature. Interestingly,
the nasal instillation of flagellin activated expression of genes
required for tissue and cellular repair, and limiting inflamma-
tion, including EGF-like growth factor amphiregulin, the DNA
repair protein GADD45b and the TGFb family factor GDF15.
Recent studies showed that flagellin stimulates survival and
proliferation of epithelial intestinal cells after abrasion of cell
monolayers.57 Beyond the role in adjuvant activity, activation of
local repair mechanisms may be crucial for the therapeutic
potential of flagellin in various models, including respiratory
infections or systemic pathologies.58,59
In conclusion, our data provided new understanding of the
mode of action of vaccine adjuvants. We defined that mucosal
adjuvant activity can be driven by signaling in airway epithelial
cells. This concept of an epithelial adjuvant may be generalized
to other adjuvants, and to the screening of new adjuvant
molecules. To this aim, it will be essential to dissect the
mechanisms that promote TLR-mediated adjuvant activity at
mucosal surfaces. Future experiments will need to identify
signals from epithelial cells involved in the recruitment and the
activation of APCs as well as the nature of APCs driving the
adjuvant effect. Finally, it is crucial to define whether these
observations are specific for flagellin and the respiratory tract or
can be extended to unrelated adjuvants or mucosa as suggested
by our experiments in the gut.
METHODS
Mice. Six-to-ten-week old C57BL/6J, C3H/HeJ, or NMRI mice were
purchased from Charles River Laboratories (Lyon, France) or Janvier
(Le Genest-Saint-Isle, France); Tlr5 / backcrossed on C57BL/6J
genetic background and congenic C57BL/6J-CD45.1 were maintained
in a specific pathogen-free facility (#A59-350009, Institut Pasteur de
Lille; Transgenose Institute CNRS, Orleans, France) and experiments
complied with national regulations and ethical guidelines (protocol
CEEA 052011).
Immunization. Mice were anesthetized by intraperitoneal injection of
ketamine–xylazine or gaseous isoflurane and were administered with
20 ml of PBS±antigens and adjuvants by i.n. route. Mice were
vaccinated i.n. on days 1 and 21 with endograde ovalbumin (OVA; 10
or 20 mg, Hyglos)±LPS-depleted Flagellin FliC from Salmonella
enterica Serovar Typhimurium produced as described18,25
(1 mg)±cholera toxin (1mg, Sigma, St Louis, MO). Bronchoalveo-
lar lavages (BALs), mediastinal lymph nodes (MdLNs), lung, spleen,
and serum were sampled on day 35. BALs were collected after the intra-
tracheal injection of 1 ml PBS with Protease Inhibitor Cocktail (Roche,
Basel, Switzerland). Lung protein extracts were prepared by homo-
genizing tissue in Tissue Protein Extraction Reagent (Pierce, Rockford,
IL) supplemented with protease inhibitors. When indicated, vaccines
were administered by IV route with 200 ml of PBS±antigens and
adjuvants.
Flagellin distribution. BALs were sampled and BAL proteins (25 mg)
were separated on SDS–polyacrylamide gel electrophoresis and blotted
on a nitrocellulose membrane (Amersham, Piscataway, NJ). Flagellin
was detected using rabbit anti-FliC polyclonal IgG,18 horseradish
peroxidise (HRP)-conjugated Goat anti-Rabbit IgG, and chimiolu-
minescent HRP reagents. Concentrations of flagellin in BAL and lung
extracts were defined by ELISA. Plates were coated with mouse anti-
FliC IgG (10 mg ml 1 in PBS). Detection was performed using the anti-
FliC antibodies conjugated to biotin, HRP-conjugated Streptavidin
(GE Healthcare, Piscataway, NJ) and the chromogenic reagent TMB.
Standard curves were used to estimate the concentration of flagellin.
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BM chimera. Recipient mice were irradiated (10–15 Gy) and
reconstituted 2–24-h later with BM cells (5–10 106 cells IV). The
mice were analyzed 3 months after BM transplantation and the degree
of chimerism was assessed by measuring CD45.1 and CD45.2
expression by leukocytes using flow cytometer as described.23 The
protocol yielded 496% of reconstitution in the blood; 490% for
Tlr5 / WT and495% for WT Tlr5 / in lung hematopoietic cells;
495% for Tlr5 / WT and 483% for WT Tlr5 / in F4/80þ
alveolar macrophages.
Antigen-specific immune responses. Levels of OVA-specific anti-
bodies in serum and BAL samples were assessed by ELISA as described.18
A reference serum has been included into individual plates to ensure
reproducibility of titer calculations. Titers are given as geometrical means
of titers from individual mice. When indicated, the concentration of
immunoglobulin was defined using a standard curve with purified IgG or
IgA (Sigma). OVA-specific T-cell responses were analyzed in mice 10–14
days after the last immunization. Spleen and MdLN cells (2–5 106)
were incubated for 72 h with RPMI-5±OVA (1 mg ml 1) to measure
secretion of IL-5, IL-13, IL-17A, IL-22, and IFN-g.
Cytokine production. Cytokine and chemokine levels were measured
in serum, BAL, lung extract, or cell culture supernatant using
commercial ELISA kits: R&D Systems (Abingdon, UK; IL-8, CCL20,
and CXCL2); eBioscience (San Diego, CA; IL-13, IL-17A, IL-22, and
IFN-g); or Becton Dickinson (Lincoln Park, NJ; IL-5 and IL-12p40).
Gene expression. Total RNA from mouse microdissected lung
compartments, whole lung, BAL, or cultured cells was extracted with
Nucleospin RNA kits (Macherey-Nagel, Duren, Germany). RNA was
reverse-transcribed with the High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). A preamplification of cDNA
from microdissected compartments was performed before real-time
PCR using the PreAmp kit (Applied Biosystems). cDNA was amplified
using SYBR Green or TaqMan assays. Relative quantification was
performed as described.23
Microarrays. Lung total RNA (0.5–2 mg) was processed on Affymetrix
GeneChip Mouse Genome 430 2.0 Array (Santa Clara, CA) or Applied
Biosystems Mouse Whole Genome Arrays (Foster City, CA).
Microarrays were analyzed respectively using the Robust Multichip
Average method and the Bioconductor Linear Models for Microarray
Data package and using the NeONORM method as described.29,30
MIAME-compliant microarray data are available at http://mace.ihes.fr
(3133411542) and www.ncbi.nlm.nih.gov/gds (GSE45369).
Laser microdissection. Whole lungs were fixed, embedded in OCT
compound (Sakura, Nagano, Japan) and frozen as described.31
Sections (15–20 mm) were stained with cresyl violet as manu-
facturer procedure (Ambion, Austin, TX). Using the LMD AS
microscope (Leica, Wetzlar, Germany), 410 samples of epithelial
layer of bronchi or alveolar regions per experiment were cut out and
collected into RNA lysis buffer.
Cell Culture. The normal human bronchial epithelial cell BEAS-2B
was grown in complete epithelial cell culture medium (Promocell
GmbH, Heidelberg, Germany). The human bronchial epithelial cell
16HBE was grown in Dulbecco’s modified Eagle’s medium (DMEM)
with 5% fetal calf serum (FCS). The human type II pneumocyte cell
A549 was grown in DMEM/F12 supplemented with 10% FCS, 10 mM
HEPES, 1 mM sodium pyruvate, nonessential amino acids. The Caco-2
human colon adenocarcinoma cell was grown in DMEM with 10%
FCS, 10 mM HEPES, and non-essential amino acids. Cells were
stimulated with 1 mg ml 1 flagellin or 1/10th dilution of BAL from
vaccinated mice.
Statistical analysis. Statistical differences were analyzed using the
Mann–Whitney test and were considered to be significant for P-values
o0.05.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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